Narus Financial Partners, LLC Biogen Inc. Transaction History

Narus Financial Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 27, 2023	BUY	$256.56 - $292.34 $230,904 - $263,106	900 New	900 $250 Million
Q4 2022 Oct 12, 2023	SELL	$252.44 - $306.72 $5,048 - $6,134	-20 Reduced 2.14%	915 $253 Million
Q3 2022 Oct 12, 2023	BUY	$194.69 - $268.46 $6,814 - $9,396	35 Added 3.89%	935 $250 Million
Q1 2022 Sep 12, 2023	BUY	$193.77 - $244.14 $13,757 - $17,333	71 Added 7.89%	971 $204 Million
Q1 2021 Mar 07, 2024	BUY	$242.95 - $284.63 $288,381 - $337,855	1,187 New	1,187 $332 Million
Q3 2019 May 14, 2024	BUY	$217.44 - $243.88 $200,044 - $224,369	920 New	920 $214 Million
Q2 2019 May 13, 2024	BUY	$219.29 - $241.72 $201,746 - $222,382	920 New	920 $215 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Narus Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Narus Financial Partners, LLC with notifications on news.